Learning From the Patient in a “Bedside-To-Bench” Approach to Cancer Research
Bladder cancer is the fifth most common cancer in the United States, predominantly affecting men in the later decades...
Category: Research
Bladder cancer is the fifth most common cancer in the United States, predominantly affecting men in the later decades...
Last week, the U.S. Food and Drug Administration (FDA) approved a new anticancer therapeutic called sonidegib (Odomzo) for patients...
Pediatric oncologist and precision medicine expert Andrew Kung, MD, PhD, of Columbia University explains.
This post explores the challenges we face with anti-EGFR monoclonal antibody therapies and new strategies researchers have developed to...
Currently, anti-EGFR therapies are approved by the U.S. Food and Drug Administration for the treatment of non-small cell lung...
This year, at the AACR Annual Meeting held in Philadelphia April 18 to 22, an astounding 19,300 members of...
In my first post in this series highlighting some of the studies presented at the AACR Annual Meeting 2015...
Tamas A. Gonda, MD, 2014 recipient of the Landon Foundation-AACR INNOVATOR Award for Cancer Prevention Research, is examining how...
Game-changing modern cancer therapies—immunotherapies and targeted therapies, among others—have been providing promising treatment outcomes in the recent years. The...
Immunotherapeutics called PD-1 inhibitors have garnered a lot of attention in the past year thanks to exciting clinical trial...